continuous glucose monitoring systems dexcom g7 Search Results


dexcom g7 system  (Dexcom Inc)
86
Dexcom Inc dexcom g7 system
Study timeline. The schematic illustrates the study timeline, including retrospective and prospective data collection periods surrounding the transition <t>from</t> <t>Dexcom</t> G6 ® to Dexcom <t>G7</t> ® (Day 0). Retrospective data collection: CGM data were retrieved at three time points before the transition (−90, −30, and −14 days), concluding the day before switching to Dexcom G7. Prospective data collection: at three time points after the transition (+14, +30, and +90 days), incorporating the day of the G7 transition in the analysis. Participants underwent two key study visits: Baseline Visit (Day 0): Included baseline questionnaires, anthropometric measurements, and HbA 1c assessment. Final Visit (+90 days): Included final questionnaires, anthropometric measurements, and HbA 1c assessment. *The day of the G7 transition is included in the prospective data downloads (+14, +30, +90). Retrospective data collection (−90, −30, −14) concludes the day before transitioning to G7. CGM, continuous glucose monitors.
Dexcom G7 System, supplied by Dexcom Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/dexcom g7 system/product/Dexcom Inc
Average 86 stars, based on 1 article reviews
dexcom g7 system - by Bioz Stars, 2026-05
86/100 stars
  Buy from Supplier
dexcom g7 cgm  (Dexcom Inc)
86
Dexcom Inc dexcom g7 cgm
Study timeline. The schematic illustrates the study timeline, including retrospective and prospective data collection periods surrounding the transition <t>from</t> <t>Dexcom</t> G6 ® to Dexcom <t>G7</t> ® (Day 0). Retrospective data collection: CGM data were retrieved at three time points before the transition (−90, −30, and −14 days), concluding the day before switching to Dexcom G7. Prospective data collection: at three time points after the transition (+14, +30, and +90 days), incorporating the day of the G7 transition in the analysis. Participants underwent two key study visits: Baseline Visit (Day 0): Included baseline questionnaires, anthropometric measurements, and HbA 1c assessment. Final Visit (+90 days): Included final questionnaires, anthropometric measurements, and HbA 1c assessment. *The day of the G7 transition is included in the prospective data downloads (+14, +30, +90). Retrospective data collection (−90, −30, −14) concludes the day before transitioning to G7. CGM, continuous glucose monitors.
Dexcom G7 Cgm, supplied by Dexcom Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/dexcom g7 cgm/product/Dexcom Inc
Average 86 stars, based on 1 article reviews
dexcom g7 cgm - by Bioz Stars, 2026-05
86/100 stars
  Buy from Supplier
sensors  (Abbott Laboratories)
86
Abbott Laboratories sensors
Study timeline. The schematic illustrates the study timeline, including retrospective and prospective data collection periods surrounding the transition <t>from</t> <t>Dexcom</t> G6 ® to Dexcom <t>G7</t> ® (Day 0). Retrospective data collection: CGM data were retrieved at three time points before the transition (−90, −30, and −14 days), concluding the day before switching to Dexcom G7. Prospective data collection: at three time points after the transition (+14, +30, and +90 days), incorporating the day of the G7 transition in the analysis. Participants underwent two key study visits: Baseline Visit (Day 0): Included baseline questionnaires, anthropometric measurements, and HbA 1c assessment. Final Visit (+90 days): Included final questionnaires, anthropometric measurements, and HbA 1c assessment. *The day of the G7 transition is included in the prospective data downloads (+14, +30, +90). Retrospective data collection (−90, −30, −14) concludes the day before transitioning to G7. CGM, continuous glucose monitors.
Sensors, supplied by Abbott Laboratories, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/sensors/product/Abbott Laboratories
Average 86 stars, based on 1 article reviews
sensors - by Bioz Stars, 2026-05
86/100 stars
  Buy from Supplier
cgm device  (Dexcom Inc)
86
Dexcom Inc cgm device
Study timeline. The schematic illustrates the study timeline, including retrospective and prospective data collection periods surrounding the transition <t>from</t> <t>Dexcom</t> G6 ® to Dexcom <t>G7</t> ® (Day 0). Retrospective data collection: CGM data were retrieved at three time points before the transition (−90, −30, and −14 days), concluding the day before switching to Dexcom G7. Prospective data collection: at three time points after the transition (+14, +30, and +90 days), incorporating the day of the G7 transition in the analysis. Participants underwent two key study visits: Baseline Visit (Day 0): Included baseline questionnaires, anthropometric measurements, and HbA 1c assessment. Final Visit (+90 days): Included final questionnaires, anthropometric measurements, and HbA 1c assessment. *The day of the G7 transition is included in the prospective data downloads (+14, +30, +90). Retrospective data collection (−90, −30, −14) concludes the day before transitioning to G7. CGM, continuous glucose monitors.
Cgm Device, supplied by Dexcom Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/cgm device/product/Dexcom Inc
Average 86 stars, based on 1 article reviews
cgm device - by Bioz Stars, 2026-05
86/100 stars
  Buy from Supplier
dexcom systems  (Dexcom Inc)
86
Dexcom Inc dexcom systems
Study timeline. The schematic illustrates the study timeline, including retrospective and prospective data collection periods surrounding the transition <t>from</t> <t>Dexcom</t> G6 ® to Dexcom <t>G7</t> ® (Day 0). Retrospective data collection: CGM data were retrieved at three time points before the transition (−90, −30, and −14 days), concluding the day before switching to Dexcom G7. Prospective data collection: at three time points after the transition (+14, +30, and +90 days), incorporating the day of the G7 transition in the analysis. Participants underwent two key study visits: Baseline Visit (Day 0): Included baseline questionnaires, anthropometric measurements, and HbA 1c assessment. Final Visit (+90 days): Included final questionnaires, anthropometric measurements, and HbA 1c assessment. *The day of the G7 transition is included in the prospective data downloads (+14, +30, +90). Retrospective data collection (−90, −30, −14) concludes the day before transitioning to G7. CGM, continuous glucose monitors.
Dexcom Systems, supplied by Dexcom Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/dexcom systems/product/Dexcom Inc
Average 86 stars, based on 1 article reviews
dexcom systems - by Bioz Stars, 2026-05
86/100 stars
  Buy from Supplier
asp biomed clin case rep case report  (Dexcom Inc)
86
Dexcom Inc asp biomed clin case rep case report
Study timeline. The schematic illustrates the study timeline, including retrospective and prospective data collection periods surrounding the transition <t>from</t> <t>Dexcom</t> G6 ® to Dexcom <t>G7</t> ® (Day 0). Retrospective data collection: CGM data were retrieved at three time points before the transition (−90, −30, and −14 days), concluding the day before switching to Dexcom G7. Prospective data collection: at three time points after the transition (+14, +30, and +90 days), incorporating the day of the G7 transition in the analysis. Participants underwent two key study visits: Baseline Visit (Day 0): Included baseline questionnaires, anthropometric measurements, and HbA 1c assessment. Final Visit (+90 days): Included final questionnaires, anthropometric measurements, and HbA 1c assessment. *The day of the G7 transition is included in the prospective data downloads (+14, +30, +90). Retrospective data collection (−90, −30, −14) concludes the day before transitioning to G7. CGM, continuous glucose monitors.
Asp Biomed Clin Case Rep Case Report, supplied by Dexcom Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/asp biomed clin case rep case report/product/Dexcom Inc
Average 86 stars, based on 1 article reviews
asp biomed clin case rep case report - by Bioz Stars, 2026-05
86/100 stars
  Buy from Supplier
cgm systems  (Dexcom Inc)
86
Dexcom Inc cgm systems
Study timeline. The schematic illustrates the study timeline, including retrospective and prospective data collection periods surrounding the transition <t>from</t> <t>Dexcom</t> G6 ® to Dexcom <t>G7</t> ® (Day 0). Retrospective data collection: CGM data were retrieved at three time points before the transition (−90, −30, and −14 days), concluding the day before switching to Dexcom G7. Prospective data collection: at three time points after the transition (+14, +30, and +90 days), incorporating the day of the G7 transition in the analysis. Participants underwent two key study visits: Baseline Visit (Day 0): Included baseline questionnaires, anthropometric measurements, and HbA 1c assessment. Final Visit (+90 days): Included final questionnaires, anthropometric measurements, and HbA 1c assessment. *The day of the G7 transition is included in the prospective data downloads (+14, +30, +90). Retrospective data collection (−90, −30, −14) concludes the day before transitioning to G7. CGM, continuous glucose monitors.
Cgm Systems, supplied by Dexcom Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/cgm systems/product/Dexcom Inc
Average 86 stars, based on 1 article reviews
cgm systems - by Bioz Stars, 2026-05
86/100 stars
  Buy from Supplier
current generation cgms  (Dexcom Inc)
86
Dexcom Inc current generation cgms
Study timeline. The schematic illustrates the study timeline, including retrospective and prospective data collection periods surrounding the transition <t>from</t> <t>Dexcom</t> G6 ® to Dexcom <t>G7</t> ® (Day 0). Retrospective data collection: CGM data were retrieved at three time points before the transition (−90, −30, and −14 days), concluding the day before switching to Dexcom G7. Prospective data collection: at three time points after the transition (+14, +30, and +90 days), incorporating the day of the G7 transition in the analysis. Participants underwent two key study visits: Baseline Visit (Day 0): Included baseline questionnaires, anthropometric measurements, and HbA 1c assessment. Final Visit (+90 days): Included final questionnaires, anthropometric measurements, and HbA 1c assessment. *The day of the G7 transition is included in the prospective data downloads (+14, +30, +90). Retrospective data collection (−90, −30, −14) concludes the day before transitioning to G7. CGM, continuous glucose monitors.
Current Generation Cgms, supplied by Dexcom Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/current generation cgms/product/Dexcom Inc
Average 86 stars, based on 1 article reviews
current generation cgms - by Bioz Stars, 2026-05
86/100 stars
  Buy from Supplier
dexcom system g7  (Dexcom Inc)
86
Dexcom Inc dexcom system g7
Study timeline. The schematic illustrates the study timeline, including retrospective and prospective data collection periods surrounding the transition <t>from</t> <t>Dexcom</t> G6 ® to Dexcom <t>G7</t> ® (Day 0). Retrospective data collection: CGM data were retrieved at three time points before the transition (−90, −30, and −14 days), concluding the day before switching to Dexcom G7. Prospective data collection: at three time points after the transition (+14, +30, and +90 days), incorporating the day of the G7 transition in the analysis. Participants underwent two key study visits: Baseline Visit (Day 0): Included baseline questionnaires, anthropometric measurements, and HbA 1c assessment. Final Visit (+90 days): Included final questionnaires, anthropometric measurements, and HbA 1c assessment. *The day of the G7 transition is included in the prospective data downloads (+14, +30, +90). Retrospective data collection (−90, −30, −14) concludes the day before transitioning to G7. CGM, continuous glucose monitors.
Dexcom System G7, supplied by Dexcom Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/dexcom system g7/product/Dexcom Inc
Average 86 stars, based on 1 article reviews
dexcom system g7 - by Bioz Stars, 2026-05
86/100 stars
  Buy from Supplier
g6 g7 freestyle libre 2 3  (Dexcom Inc)
86
Dexcom Inc g6 g7 freestyle libre 2 3
Study timeline. The schematic illustrates the study timeline, including retrospective and prospective data collection periods surrounding the transition <t>from</t> <t>Dexcom</t> G6 ® to Dexcom <t>G7</t> ® (Day 0). Retrospective data collection: CGM data were retrieved at three time points before the transition (−90, −30, and −14 days), concluding the day before switching to Dexcom G7. Prospective data collection: at three time points after the transition (+14, +30, and +90 days), incorporating the day of the G7 transition in the analysis. Participants underwent two key study visits: Baseline Visit (Day 0): Included baseline questionnaires, anthropometric measurements, and HbA 1c assessment. Final Visit (+90 days): Included final questionnaires, anthropometric measurements, and HbA 1c assessment. *The day of the G7 transition is included in the prospective data downloads (+14, +30, +90). Retrospective data collection (−90, −30, −14) concludes the day before transitioning to G7. CGM, continuous glucose monitors.
G6 G7 Freestyle Libre 2 3, supplied by Dexcom Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/g6 g7 freestyle libre 2 3/product/Dexcom Inc
Average 86 stars, based on 1 article reviews
g6 g7 freestyle libre 2 3 - by Bioz Stars, 2026-05
86/100 stars
  Buy from Supplier
dexcom sensors  (Dexcom Inc)
86
Dexcom Inc dexcom sensors
Study timeline. The schematic illustrates the study timeline, including retrospective and prospective data collection periods surrounding the transition <t>from</t> <t>Dexcom</t> G6 ® to Dexcom <t>G7</t> ® (Day 0). Retrospective data collection: CGM data were retrieved at three time points before the transition (−90, −30, and −14 days), concluding the day before switching to Dexcom G7. Prospective data collection: at three time points after the transition (+14, +30, and +90 days), incorporating the day of the G7 transition in the analysis. Participants underwent two key study visits: Baseline Visit (Day 0): Included baseline questionnaires, anthropometric measurements, and HbA 1c assessment. Final Visit (+90 days): Included final questionnaires, anthropometric measurements, and HbA 1c assessment. *The day of the G7 transition is included in the prospective data downloads (+14, +30, +90). Retrospective data collection (−90, −30, −14) concludes the day before transitioning to G7. CGM, continuous glucose monitors.
Dexcom Sensors, supplied by Dexcom Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/dexcom sensors/product/Dexcom Inc
Average 86 stars, based on 1 article reviews
dexcom sensors - by Bioz Stars, 2026-05
86/100 stars
  Buy from Supplier
diabetes approved devices  (Abbott Laboratories)
86
Abbott Laboratories diabetes approved devices
Study timeline. The schematic illustrates the study timeline, including retrospective and prospective data collection periods surrounding the transition <t>from</t> <t>Dexcom</t> G6 ® to Dexcom <t>G7</t> ® (Day 0). Retrospective data collection: CGM data were retrieved at three time points before the transition (−90, −30, and −14 days), concluding the day before switching to Dexcom G7. Prospective data collection: at three time points after the transition (+14, +30, and +90 days), incorporating the day of the G7 transition in the analysis. Participants underwent two key study visits: Baseline Visit (Day 0): Included baseline questionnaires, anthropometric measurements, and HbA 1c assessment. Final Visit (+90 days): Included final questionnaires, anthropometric measurements, and HbA 1c assessment. *The day of the G7 transition is included in the prospective data downloads (+14, +30, +90). Retrospective data collection (−90, −30, −14) concludes the day before transitioning to G7. CGM, continuous glucose monitors.
Diabetes Approved Devices, supplied by Abbott Laboratories, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/diabetes approved devices/product/Abbott Laboratories
Average 86 stars, based on 1 article reviews
diabetes approved devices - by Bioz Stars, 2026-05
86/100 stars
  Buy from Supplier

Image Search Results


Study timeline. The schematic illustrates the study timeline, including retrospective and prospective data collection periods surrounding the transition from Dexcom G6 ® to Dexcom G7 ® (Day 0). Retrospective data collection: CGM data were retrieved at three time points before the transition (−90, −30, and −14 days), concluding the day before switching to Dexcom G7. Prospective data collection: at three time points after the transition (+14, +30, and +90 days), incorporating the day of the G7 transition in the analysis. Participants underwent two key study visits: Baseline Visit (Day 0): Included baseline questionnaires, anthropometric measurements, and HbA 1c assessment. Final Visit (+90 days): Included final questionnaires, anthropometric measurements, and HbA 1c assessment. *The day of the G7 transition is included in the prospective data downloads (+14, +30, +90). Retrospective data collection (−90, −30, −14) concludes the day before transitioning to G7. CGM, continuous glucose monitors.

Journal: Therapeutic Advances in Endocrinology and Metabolism

Article Title: Prospective multicenter evaluation of glycemic and patient-reported outcomes following transition to a next-generation continuous glucose monitoring system in users of advanced hybrid closed-loop technology

doi: 10.1177/20420188251407515

Figure Lengend Snippet: Study timeline. The schematic illustrates the study timeline, including retrospective and prospective data collection periods surrounding the transition from Dexcom G6 ® to Dexcom G7 ® (Day 0). Retrospective data collection: CGM data were retrieved at three time points before the transition (−90, −30, and −14 days), concluding the day before switching to Dexcom G7. Prospective data collection: at three time points after the transition (+14, +30, and +90 days), incorporating the day of the G7 transition in the analysis. Participants underwent two key study visits: Baseline Visit (Day 0): Included baseline questionnaires, anthropometric measurements, and HbA 1c assessment. Final Visit (+90 days): Included final questionnaires, anthropometric measurements, and HbA 1c assessment. *The day of the G7 transition is included in the prospective data downloads (+14, +30, +90). Retrospective data collection (−90, −30, −14) concludes the day before transitioning to G7. CGM, continuous glucose monitors.

Article Snippet: Additionally, 27 out of 92 participants (29.3%) reported issues related to the Dexcom G7 system.

Techniques:

Changes in glycemic metrics following the transition from Dexcom G6 ® to Dexcom G7 ® in participants with baseline TIR 70–180 <70%. Stacked bar graphs represent the percentage of time spent in different glycemic ranges at each time point, comparing retrospective data collected with Dexcom G6 (days −90, −30, and −14) and prospective data collected with Dexcom G7 (days +14, +30, and +90). Green: TIR 70–180 ; Yellow: TAR >180 ; Orange: TAR >250 ; Red: TBR <70 . Statistically significant improvements were observed in TIR 70–180 ( p = 0.007), TAR >250 ( p = 0.003), and total TAR >180 ( p = 0.024) at day +90 compared to baseline measurements. TAR, time above range; TBR, time below range; TIR, time in range between 70 and 180 mg/dL.

Journal: Therapeutic Advances in Endocrinology and Metabolism

Article Title: Prospective multicenter evaluation of glycemic and patient-reported outcomes following transition to a next-generation continuous glucose monitoring system in users of advanced hybrid closed-loop technology

doi: 10.1177/20420188251407515

Figure Lengend Snippet: Changes in glycemic metrics following the transition from Dexcom G6 ® to Dexcom G7 ® in participants with baseline TIR 70–180 <70%. Stacked bar graphs represent the percentage of time spent in different glycemic ranges at each time point, comparing retrospective data collected with Dexcom G6 (days −90, −30, and −14) and prospective data collected with Dexcom G7 (days +14, +30, and +90). Green: TIR 70–180 ; Yellow: TAR >180 ; Orange: TAR >250 ; Red: TBR <70 . Statistically significant improvements were observed in TIR 70–180 ( p = 0.007), TAR >250 ( p = 0.003), and total TAR >180 ( p = 0.024) at day +90 compared to baseline measurements. TAR, time above range; TBR, time below range; TIR, time in range between 70 and 180 mg/dL.

Article Snippet: Additionally, 27 out of 92 participants (29.3%) reported issues related to the Dexcom G7 system.

Techniques: